199 related articles for article (PubMed ID: 21325066)
1. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
Khan AJ; Wall B; Ahlawat S; Green C; Schiff D; Mehnert JM; Goydos JS; Chen S; Haffty BG
Clin Cancer Res; 2011 Apr; 17(7):1807-14. PubMed ID: 21325066
[TBL] [Abstract][Full Text] [Related]
2. Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.
Wall BA; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2015 Jan; 28(1):105-9. PubMed ID: 25363352
[TBL] [Abstract][Full Text] [Related]
3. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
4. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
Wall BA; Wangari-Talbot J; Shin SS; Schiff D; Sierra J; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2014 Mar; 27(2):263-74. PubMed ID: 24330389
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Baschnagel A; Russo A; Burgan WE; Carter D; Beam K; Palmieri D; Steeg PS; Tofilon P; Camphausen K
Mol Cancer Ther; 2009 Jun; 8(6):1589-95. PubMed ID: 19509253
[TBL] [Abstract][Full Text] [Related]
6. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.
Le MN; Chan JL; Rosenberg SA; Nabatian AS; Merrigan KT; Cohen-Solal KA; Goydos JS
J Invest Dermatol; 2010 Sep; 130(9):2240-9. PubMed ID: 20505744
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.
Petersen C; Petersen S; Milas L; Lang FF; Tofilon PJ
Clin Cancer Res; 2000 Jun; 6(6):2513-20. PubMed ID: 10873107
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Speyer CL; Smith JS; Banda M; DeVries JA; Mekani T; Gorski DH
Breast Cancer Res Treat; 2012 Apr; 132(2):565-73. PubMed ID: 21681448
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Namkoong J; Shin SS; Lee HJ; Marín YE; Wall BA; Goydos JS; Chen S
Cancer Res; 2007 Mar; 67(5):2298-305. PubMed ID: 17332361
[TBL] [Abstract][Full Text] [Related]
11. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.
Yip D; Le MN; Chan JL; Lee JH; Mehnert JA; Yudd A; Kempf J; Shih WJ; Chen S; Goydos JS
Clin Cancer Res; 2009 Jun; 15(11):3896-902. PubMed ID: 19458050
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway.
Zhang C; Yuan XR; Li HY; Zhao ZJ; Liao YW; Wang XY; Su J; Sang SS; Liu Q
Cell Physiol Biochem; 2015; 35(2):419-32. PubMed ID: 25613036
[TBL] [Abstract][Full Text] [Related]
13. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
Torres MA; Raju U; Molkentine D; Riesterer O; Milas L; Ang KK
Invest New Drugs; 2011 Aug; 29(4):554-61. PubMed ID: 20119866
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.
Chu SH; Karri S; Ma YB; Feng DF; Li ZQ
Neuro Oncol; 2013 Jul; 15(7):880-90. PubMed ID: 23519742
[TBL] [Abstract][Full Text] [Related]
15. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
Harada T; Harada K; Ueyama Y
Int J Oncol; 2012 Aug; 41(2):565-72. PubMed ID: 22664937
[TBL] [Abstract][Full Text] [Related]
16. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Wen Y; Li J; Koo J; Shin SS; Lin Y; Jeong BS; Mehnert JM; Chen S; Cohen-Sola KA; Goydos JS
Cancer Res; 2014 May; 74(9):2499-509. PubMed ID: 24491800
[TBL] [Abstract][Full Text] [Related]
17. The current management of brain metastasis in melanoma: a focus on riluzole.
Yu LJ; Wall BA; Chen S
Expert Rev Neurother; 2015; 15(7):779-92. PubMed ID: 26092602
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
19. The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells,
Khan AJ; LaCava S; Mehta M; Schiff D; Thandoni A; Jhawar S; Danish S; Haffty BG; Chen S
Oncotarget; 2019 Apr; 10(29):2824-2834. PubMed ID: 31073373
[TBL] [Abstract][Full Text] [Related]
20. Nelfinavir induces radiation sensitization in pituitary adenoma cells.
Zeng J; See AP; Aziz K; Thiyagarajan S; Salih T; Gajula RP; Armour M; Phallen J; Terezakis S; Kleinberg L; Redmond K; Hales RK; Salvatori R; Quinones-Hinojosa A; Tran PT; Lim M
Cancer Biol Ther; 2011 Oct; 12(7):657-63. PubMed ID: 21811091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
